TY - JOUR
T1 - Characterization of an umbilical cord blood sourced product suitable for allogeneic applications
AU - Sane, Mukta S.
AU - Tang, Huiyuan
AU - Misra, Neha
AU - Pu, Xinzhu
AU - Malara, Sara
AU - Jones, Christopher D.
AU - Mustafi, Soumyajit Banerjee
N1 - Publisher Copyright:
© 2019 Future Medicine Ltd.
PY - 2019
Y1 - 2019
N2 - Aim: Umbilical cord blood (UCB) sourced allografts are promising interventions for tissue regeneration. As applications of these allografts and regulations governing them continue to evolve, we were prompted to identify parameters determining their quality, safety and regenerative potential. Materials & methods: Flow-cytometry, mass-spectrometry, protein multiplexing, nanoparticle tracking analysis and standard biological techniques were employed. Results: Quality attributes of a uniquely processed UCB-allograft (UCBr) were enumerated based on identity (cell viability, immunophenotyping, proteomic profiling, and quantification of relevant cytokines); safety (bioburden and microbiological screening), purity (endotoxin levels) and potency (effect of UCBr on chondrocytes and mesenchymal stem cells derived exosomes). These attributes were stable up to 24 months in cryopreserved UCBr. Conclusion: We identified a comprehensive panel of tests to establish the clinical efficacy and quality control attributes of a UCB-sourced allograft.
AB - Aim: Umbilical cord blood (UCB) sourced allografts are promising interventions for tissue regeneration. As applications of these allografts and regulations governing them continue to evolve, we were prompted to identify parameters determining their quality, safety and regenerative potential. Materials & methods: Flow-cytometry, mass-spectrometry, protein multiplexing, nanoparticle tracking analysis and standard biological techniques were employed. Results: Quality attributes of a uniquely processed UCB-allograft (UCBr) were enumerated based on identity (cell viability, immunophenotyping, proteomic profiling, and quantification of relevant cytokines); safety (bioburden and microbiological screening), purity (endotoxin levels) and potency (effect of UCBr on chondrocytes and mesenchymal stem cells derived exosomes). These attributes were stable up to 24 months in cryopreserved UCBr. Conclusion: We identified a comprehensive panel of tests to establish the clinical efficacy and quality control attributes of a UCB-sourced allograft.
KW - endotoxin
KW - exosomes
KW - graft versus host disease
KW - quality control
KW - tissue regeneration
UR - http://www.scopus.com/inward/record.url?scp=85072064668&partnerID=8YFLogxK
U2 - 10.2217/rme-2019-0058
DO - 10.2217/rme-2019-0058
M3 - Article
C2 - 31313975
AN - SCOPUS:85072064668
SN - 1746-0751
VL - 14
SP - 769
EP - 789
JO - Regenerative Medicine
JF - Regenerative Medicine
IS - 8
ER -